Brian Adams - 02 Mar 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Reporting relationship: Chief Legal Officer
Issuer ticker: KYMR
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 18:00:10 UTC
Prior SEC filing: 03 Sep 2025
Next SEC filing: 04 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Bruce Jacobs, as Attorney-in-Fact

Filing notes and source

Key filing fact

Brian Adams filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 04 Mar 2026.

Key facts

This page summarizes Brian Adams's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2026, 18:00.

Change

Previous filing in this sequence was filed on 03 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001636994 Primary reporting owner

Adams Brian

Relationship: Chief Legal Officer
Address: 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYMR transaction

Common Stock

Award

Transaction value
Shares: +4,125
Change %: +7.9%
Price: $0.000000^*
Shares after: 56,625
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +8,250
Change %
Price: $0.000000^*
Shares after: 8,250
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,250
Exercise price: $90.10
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

Footnote F2

The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.